title: Serum level of soluble interleukin-2 receptor in patients with seasonal allergic rhinitis.
abstract: The rate of release of the soluble form of interleukin-2 receptor (soluble IL-2R) reflects T cell activation in vivo. Since T lymphocytes play a central role in respiratory allergic disorders, the measurement of serum levels of soluble IL-2R may be useful in analysing the disease state of allergic disorders. The study has aimed at investigating the seasonal changes in serum soluble IL-2R in 81 patients with seasonal allergic rhinitis due to Japanese cedar pollens, with special reference to the effect of anti-allergic pharmacotherapy and immunotherapy. Serum samples were obtained twice from each patient, before and during the pollen season, and all the serum samples were simultaneously used for determination of soluble IL-2R and cedar pollen-specific immunoglobin E (IgE). Seasonal elevation in soluble IL-2R was not associated with the good clinical outcome but was associated with the poor clinical outcome, irrespective of pharmacotherapy or immunotherapy. Additionally, successful immunotherapy suppressed seasonal elevation of serum soluble IL-2R more strongly than successful pharmacotherapy, and seasonal increase rates in soluble IL-2R were inversely correlated with the duration of immunotherapy. Seasonal increase rates in soluble IL-2R were significantly correlated with seasonal increase rates in specific IgE in both the medication group and the immunotherapy patients. These results may suggest that seasonal changes in serum soluble IL-2R may serve as an indicator for clinical outcome of seasonal allergic rhinitis, that the magnitude of T cell activation could affect specific IgE production, and that T cell activation could be gradually modulated as immunotherapy proceeds. In conclusion, seasonal changes in serum soluble IL-2R may serve as an objective indicator for clinical outcome of seasonal allergic rhinitis.
authors.affiliation: Department of Otolaryngology, Osaka City University Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: A
authors.initials: A
authors.lastname: Tanaka
authors.forename: Y
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: Y
authors.initials: Y
authors.lastname: Ohno
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: T
authors.initials: T
authors.lastname: Masamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Wahio
authors.forename: Y
authors.initials: Y
authors.lastname: Nakai
mesh_terms: D000293:Adolescent; D000328:Adult; D000918:Antibody Specificity; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000097:blood*; D006255:Rhinitis, Allergic, Seasonal / Q000097:blood* / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy
chemical_list: D015375:Receptors, Interleukin-2; D007073:Immunoglobulin E